Foley & Lardner LLP Partner Jason Kohout is quoted in the Bloomberg article, “Renaissance Ends No-Fee Investment Perk After IRS Complaints,” about how Renaissance Technologies has ended its no-fee Medallion investment fund for employees after the IRS argued that such fee waivers should be considered taxable compensation.
Kohout said that while it is murky territory, “It is kind of common to say ‘we are not going to take compensation to avoid any self-dealing issues.’”
“IRS guidance in this area is pretty limited, especially when it comes to the ways investment managers are paid,” he added.
The article also ran in Accounting Today and Financial Advisor.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”